GPR162

Chr 12

G protein-coupled receptor 162

Also known as: A-2, GRCA

GPR162 encodes an orphan G-protein coupled receptor that is primarily expressed in the brain, though its specific function remains unknown. Mutations in this gene cause autosomal recessive developmental and epileptic encephalopathy with severe intellectual disability and early-onset seizures. The gene shows moderate constraint against loss-of-function variants (LOEUF 0.659), consistent with its role in neurodevelopment.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
1
Pubs (1 yr)
45
P/LP submissions
0%
P/LP missense
0.66
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryGPR162
Population Constraint (gnomAD)
Low constraint (pLI 0.01) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
45 unique Pathogenic / Likely Pathogenic· 104 VUS of 160 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
0.66LOEUF
pLI 0.009
Z-score 2.69
OE 0.35 (0.200.66)
Tolerant

Typical tolerance to LoF variation

Missense Constraint
0.89Z-score
OE missense 0.87 (0.800.95)
330 obs / 379.0 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.35 (0.200.66)
00.351.4
Missense OE0.87 (0.800.95)
00.61.4
Synonymous OE1.24
01.21.6
LoF obs/exp: 7 / 20.0Missense obs/exp: 330 / 379.0Syn Z: -2.42
DN
0.6937th %ile
GOF
0.79top 25%
LOF
0.4136th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

160 submitted variants in ClinVar

Classification Summary

Pathogenic43
Likely Pathogenic2
VUS104
Likely Benign1
Benign2
43
Pathogenic
2
Likely Pathogenic
104
VUS
1
Likely Benign
2
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
43
0
43
Likely Pathogenic
0
0
2
0
2
VUS
0
93
11
0
104
Likely Benign
0
1
0
0
1
Benign
1
0
0
1
2
Total194561152

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

GPR162 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →